ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Seffrin, Thomas Lead List of ACS Exec. VP Candidates, Reportedly

May 1, 1992

ONS Forms More Special Interest Groups For Members

May 11, 1990

Interactive RPGs Deadline Is Feb. 20

December 13, 1991

HHS Forms Office for Recovery Act

March 13, 2009

Univ. Of Washington, Fox Chase, ICC Win CCRU, CCSP Awards

July 8, 1983

The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation

May 14, 2010